T
Temedica
Biotech & Life Sciences · Munich, Germany · Founded 2016
Health insights ecosystem for real-world evidence MoreLess
Temedica is a digital health company founded in 2016 in Munich, Germany, by Gloria Seibert and Benjamin Friedrich. Gloria Seibert, the CEO, was motivated to start the company due to her grandfather's battle with multiple sclerosis, which highlighted the need for more personalized patient support. Before Temedica, she worked as a business consultant at McKinsey and studied software engineering in Silicon Valley to gain the necessary technological expertise. Co-founder and Chief Medical Officer, PD Dr. med Benjamin Friedrich, brings extensive medical and academic experience from his work in radiology and neuroradiology at institutions like the Technical University of Munich.
The company operates a health insights ecosystem designed to centralize and analyze health data from various sources to generate real-world evidence. This ecosystem serves a wide range of clients, including pharmaceutical companies, research institutions, healthcare professionals, and patients. Temedica's business model is centered on partnerships with pharmaceutical firms, providing them with anonymized, GDPR-compliant data that offers insights into disease progression, patient journeys, and treatment effectiveness outside of traditional clinical trials. Partners have included major companies like Roche and AbbVie Germany.
Temedica's core offerings include digital patient companion apps and the Permea real-world insights platform. The companion apps are designed for patients with chronic conditions such as multiple sclerosis, psoriasis, and cancer, offering personalized guidance and support. The Permea platform integrates patient-generated data from these apps with other sources like registry and insurance data to provide a comprehensive view of patient care realities. This allows clients to receive customized analytics and reports that inform strategic decisions in areas like product development, market strategy, and patient engagement. The company has raised a total of $44.6 million in funding, including a Series B round that closed in November 2022.
Keywords: real-world evidence, health insights, digital health, patient journey, data analytics, personalized medicine, digital patient companion, pharma solutions, chronic disease management, healthcare data, real-world data, Permea, health-tech, patient-generated data, omnichannel engagement, disease progression, treatment effectiveness, medication adherence, clinical research, patient-centric care
Company overview
Temedica company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2016
- Headquarters
- Munich, Germany
- Employees
- 67
- Open positions
- 3
- Dealroom signal
- 70.6
Valuation & funding
Temedica funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Nov 2022 | $28M | $110M | MIG Capital | ↗ |
| SERIES A✓Equity / VC | Jan 2020 | $19M | $75M | G+J Ventures · MIG Capital · Bernd Wendeln · Santo Venture Capital | ↗ |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | Profit | Margin |
|---|---|---|---|---|
| 2026 | $3.3M | 0% | −$10M | -313.6% |
| 2025 | $3.3M | 0% | −$10M | -313.6% |
| 2024 | $3.3M | 0% | −$10M | -313.6% |
| 2023 | $3.3M | 0% | ||
| 2022 | $3.3M | 0% | ||
| 2021 | $3.3M | +200% | ||
| 2020 | $1.1M | — |
Growth signals
Temedica website traffic
Latest recorded traffic for Temedica is 5.4K monthly website visits, down 19.4% over the last three months. Temedica's team declined 6.9% over the past year.
Hiring
Open positions at Temedica
Current openings linked to this company in Dealroom.
Comparisons
Temedica compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Temedica's talent
Source: Dealroom Talent Intelligence.
Investors
6 investors on Temedica's cap table
Sourced from Dealroom's funding and investor records.





Global footprint
Where Temedica has talent and traffic
team presence
In the news
Latest news about Temedica
Recent press, funding announcements, and product moves mentioning Temedica — open to read from the original sources.
Market sentiment
What the market is saying about Temedica
An AI-synthesized read of the highest-engagement posts about Temedica on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Temedica’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







